Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

The Latest Breaking News from Lung Cancer

Dear Abby: Lung cancer killed my mother, and rude people keep asking if she smoked

It’s as if they think people with a tobacco habit deserve to die.

Chicago Sun-Times

Mum told she had a 'trapped nerve' finds out she has lung cancer

Mum told she had a 'trapped nerve' finds out she has lung cancer

Andrea Fenn started suffering with severe shoulder and spine pain

Turning Point Inks Licensing Pact For Gastrointestinal Cancers Candidate

Turning Point Inks Licensing Pact For Gastrointestinal Cancers Candidate

Turning Point Therapeutics Inc (NASDAQ:TPTX) entered into an exclusive license agreement with LaNova Medicines Limited to develop and commercialize LM-302, in the U.S. and the rest of the world, excluding Greater China and South Korea. LM-302 is a novel antibody-drug conjugate (ADC) targeting Claudin18.2, a protein expressed in many gastrointestinal cancers, including gastric, gastroesophageal junction,…

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Galera Posts Topline Data From Avasopasem Study In Chemoradiotherapy-Induced Esophagitis

Galera Therapeutics Inc (NASDAQ:GRTX) announced topline results from Phase 2a AESOP trial of avasopasem for severe acute radiation-induced esophagitis in lung cancer patients receiving concurrent chemoradiotherapy. Esophagitis is an early side effect of radiation or chemoradiation, causing pain, difficulties in swallowing with potential malnutrition, and dehydration. The trial enrolled 39 patients with unresectable…

FDA Rejects Junshi - Coherus' Toripalimab For Rare Head & Neck Cancer

The FDA has issued a complete response letter (CRL) to Junshi Biosciences Co Ltd and Coherus BioSciences Inc's (NASDAQ:CHRS) toripalimab application for advanced recurrent or metastatic nasopharyngeal carcinoma (NPC). NPC is a rare tumor of the head and neck which originates in the nasopharynx, located behind the nose and above the back of the throat. The…

AstraZeneca Clocks Q1 COVID Vaccine Sales Of $1.2B, Keeps Overall FY22 Outlook

AstraZeneca Plc's (NASDAQ:AZN) total revenue jumped 60% Y/Y at CER to $11.39 billion in Q1 FY22, beating the consensus of $10.99 billion. The growth reflects the contribution of the Alexion medicines and several Vaxzevria contracts that are expected to complete the delivery by half year 2022. Core EPS came in at $1.89,…

Novartis - BeiGene's Tislelizumab Aces Late-Stage Esophageal Cancer Trial

Novartis AG (NYSE:NVS) has announced topline results from an interim analysis of the Phase 3 RATIONALE 306 study of tislelizumab plus chemotherapy in esophageal squamous cell carcinoma (ESCC). Data showed that tislelizumab plus chemotherapy significantly improved overall survival (OS) compared to chemotherapy in patients with previously untreated unresectable, locally advanced, recurrent, or metastatic…

inkl

Read news from The Economist, FT, and more,
with one subscription

Daiichi Sankyo - AstraZeneca's Enhertu Receives Third Breakthrough Therapy Tag In Breast Cancer

Daiichi Sankyo - AstraZeneca's Enhertu Receives Third Breakthrough Therapy Tag In Breast Cancer

The FDA has granted Breakthrough Therapy Designation (BTD) to Daiichi Sankyo (OTC:DSKYF) and AstraZeneca Plc's (NASDAQ:AZN) Enhertu (fam-trastuzumab deruxtecan-nxki) for unresectable or metastatic HER2 low (IHC 1+ or IHC 2+/ISH-negative) breast cancer. The designation covers patients who have received a prior systemic therapy in the metastatic setting or developed disease recurrence during or within six months…

AI tool accurately predicts tumour regrowth in cancer patients

AI tool accurately predicts tumour regrowth in cancer patients

Exclusive: Tool predicts how likely tumours are to grow back in cancer patients after they have undergone treatment

The Guardian - UK

EMA' Advisory Committee Recommends Approval For Roche's Two Cancer Drugs

EMA' Advisory Committee Recommends Approval For Roche's Two Cancer Drugs

The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended conditional approval for Roche Holdings AG's (OTC:RHHBY) mosunetuzumab for relapsed or refractory (R/R) follicular lymphoma (FL). The opinion covers mosunetuzumab for adult patients who have received at least two prior systemic therapies. The CHMP recommendation is based on…

NHS England issues stark warning to anyone who has smoked cigarettes

NHS England issues stark warning to anyone who has smoked cigarettes

People most at risk of lung cancer are being urged to attend checks aimed at catching the disease early if they receive an invite

1 … 26 27 28 29

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Imperial College London

AstraZeneca Plc

European Medicines Agency

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

378,210 stories

139,920 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play